| Bioactivity | Plutavimab a humanized IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD)[1][2]. |
| Name | Plutavimab |
| CAS | 2529854-88-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Williams, et al. Engineering of antibodies to coronavirus SARS-CoV-2 for diagnosis and treatment. World Intellectual Property Organization, WO2023070051 A1. 2023-04-27. [2]. Plutavimab. IMGT/mAb-DB. |